Why the study?
The study was conducted to analyze the clinical manifestations and treatment of patients with hemodynamically unstable lupus myocarditis.
Does VA-ECMO combined with high-dose hormones improve survival and allow weaning in patients with hemodynamically unstable lupus myocarditis?
Does VA-ECMO combined with high-dose hormones improve survival and allow weaning in patients with hemodynamically unstable lupus myocarditis?
VA-ECMO can successfully bridge patients with hemodynamically unstable lupus myocarditis and cardiogenic shock to recovery while high-dose immunosuppression takes effect.
Answers are grounded in this paper and cite their sources.
Early VA-ECMO may temporize shock in lupus myocarditis; leaves open survival benefit and should not yet change practice.
Objective: The clinical manifestations and treatment of three patients with hemodynamically unstable lupus myocarditis (LM) were analyzed. Methods: The clinical data of three patients with LM with hemodynamic instability, who were admitted to the emergency ICU of the south hospital of the Renji Hospital, School of Medicine, Shanghai Jiao Tong University of Medicine from January 2018 to December 2021, were collected and analyzed, and relevant literatures were reviewed. Results: Two of the three patients had the first onset of systemic lupus erythematosus. The other patient had mixed connective tissue disease in the past, and lupus was the main manifestation of this disease. At the onset of the disease, all patients had chest tightness and shortness of breath; two patients had a fever, and the markers of myocardial injury increased. Cardiac color Doppler ultrasound indicated that left ventricular ejection fraction decreased significantly. Cardiac insufficiency with cardiogenic shock rapidly appeared as the main manifestation. Two patients immediately started veno-arterial extracorporeal membrane oxygenation (VA-ECMO), and ECMO was also started in one patient after a pacemaker placement was ineffective. For all three patients, high-dose hormones were given to control the primary disease, and then the ECMO machines were removed successfully. Conclusion: VA-ECMO treatment should be implemented in patients with hemodynamically unstable LM as soon as possible to maintain the patient's hemodynamics and help them overcome the crisis of cardiac dysfunction, allowing more time for primary disease treatment.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: